

Anti-Amyloid Beta Antibody (Solanezumab)

Introduction

Solanezumab is a humanized monoclonal IgG1 antibody targeting the middle domain of the amyloid- β (A β) peptide. Solanezumab has the potential for Alzheimer's disease research.

Product parameters

Alternative Names	LY2062430, m266, 10D5
Target Accession	P05067
Target	Amyloid Beta
CAS number	955085-14-0
Molecular Weight	144.34 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The purity of Anti-Amyloid Beta Antibody (Solanezumab) is 96.84%, determined by SEC-HPLC.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

